ERBB2 and neoplasm: Compared to the 2 h post-injection biodistribution, higher tumor-to-blood ratios were obtained for both HER2-negative (0.74 versus 0.36) and HER2-positive (0.89 versus 0.55) at the 1 h timepoint (Figure S5B).